Key result
Infusion of rt-PA induced coronary thrombolysis in 83% of patients with evolving myocardial infarction, with a plasma half-life of approximately 9 minutes.
Why the study?
What are the pharmacokinetic properties and thrombolytic effects of rt-PA in patients with evolving myocardial infarction?
What are the pharmacokinetic properties and thrombolytic effects of rt-PA in patients with evolving myocardial infarction?
rt-PA infusion in patients with evolving myocardial infarction achieves rapid, dose-proportional peak plasma levels with a short half-life and effectively induces coronary thrombolysis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for rt-PA in evolving MI; larger randomized trials needed before clinical adoption.
This study was performed to characterize selected pharmacologic properties and effects on the fibrinolytic system of tissue-type plasminogen activator synthesized by recombinant DNA technology (rt-PA) in 12 patients treated for coronary thrombosis. rt-PA was infused parenterally (by the intracoronary route in four patients and intravenously in eight) in doses of 8.3, 12.5, or 16.7 micrograms/kg/min for 30 to 60 min, yielding a total dosage of 20 to 40 mg/patient. The drug induced coronary thrombolysis in 10 of the 12 patients treated (83%), including six of the eight given rt-PA intravenously. No bleeding complications were encountered. Serial blood samples were obtained before, during, and after infusion of rt-PA and analyzed for t-PA antigen (i.e., immunoassayable rt-PA protein), functional fibrinolytic activity attributable to rt-PA, fibrinogen, plasminogen, alpha 2-antiplasmin, fibrinogen degradation products, prothrombin time, activated partial thromboplastin time, and protamine-corrected thrombin time. Pretreatment plasma t-PA antigen levels averaged 16.5 +/- 5(SD) ng/ml. Peak plasma values were generally proportional to dose, averaging 3330 +/- 1201 ng/ml. Approximately 90% of peak level was reached in 30 min, with a plateau at peak reached within 40 min. Functional t-PA activity increased monotonically in a comparable fashion. Curves for disappearance of both t-PA antigen and functional activity from plasma were monoexponential for at least two half-lives (r = .99 for both) and were concordant. The observed half-lives were similar, averaging 8.3 and 9.1 min, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Robinson et al. (1985) studied evolving myocardial infarction (n=12). tissue-type plasminogen activator (rt-PA) was evaluated on coronary thrombolysis. Infusion of rt-PA induced coronary thrombolysis in 83% of patients with evolving myocardial infarction, with a plasma half-life of approximately 9 minutes.
Synapse has enriched 10 related papers. Consider them for comparative context: